FI944602A0 - Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit - Google Patents

Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit

Info

Publication number
FI944602A0
FI944602A0 FI944602A FI944602A FI944602A0 FI 944602 A0 FI944602 A0 FI 944602A0 FI 944602 A FI944602 A FI 944602A FI 944602 A FI944602 A FI 944602A FI 944602 A0 FI944602 A0 FI 944602A0
Authority
FI
Finland
Prior art keywords
pharmaceutically active
bicyclic heterocyclic
heterocyclic amines
active bicyclic
xxx
Prior art date
Application number
FI944602A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI944602A (fi
Inventor
Donald E Ayer
Gordon L Bundy
Eric Jon Jacobsen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI944602A0 publication Critical patent/FI944602A0/fi
Publication of FI944602A publication Critical patent/FI944602A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI944602A 1992-04-03 1994-10-03 Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit FI944602A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86364692A 1992-04-03 1992-04-03
PCT/US1993/002188 WO1993020078A1 (en) 1992-04-03 1993-03-16 Pharmaceutically active bicyclic-heterocyclic amines

Publications (2)

Publication Number Publication Date
FI944602A0 true FI944602A0 (fi) 1994-10-03
FI944602A FI944602A (fi) 1994-10-03

Family

ID=25341481

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944602A FI944602A (fi) 1992-04-03 1994-10-03 Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit

Country Status (21)

Country Link
EP (1) EP0633886B1 (cs)
JP (1) JPH08502721A (cs)
KR (1) KR100284473B1 (cs)
AT (1) ATE197051T1 (cs)
AU (1) AU675932B2 (cs)
CA (1) CA2130937A1 (cs)
CZ (1) CZ236494A3 (cs)
DE (1) DE69329574T2 (cs)
DK (1) DK0633886T3 (cs)
ES (1) ES2150941T3 (cs)
FI (1) FI944602A (cs)
GR (1) GR3035188T3 (cs)
HU (1) HUT70954A (cs)
LV (1) LV12794B (cs)
MX (1) MX9301847A (cs)
NO (1) NO303542B1 (cs)
PL (2) PL175327B1 (cs)
PT (1) PT633886E (cs)
RU (1) RU2103272C1 (cs)
SK (1) SK119194A3 (cs)
WO (1) WO1993020078A1 (cs)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177354A (zh) * 1995-03-02 1998-03-25 法玛西雅厄普约翰美国公司 嘧啶并[4,5－b]吲哚
US6180643B1 (en) 1996-11-19 2001-01-30 Amgen Inc. Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
WO1998024453A1 (fr) * 1996-12-05 1998-06-11 Nippon Shinyaku Co., Ltd. Medicaments pour la myelopathie
NZ336659A (en) * 1997-01-08 2001-01-26 Upjohn Co Pharmaceutically active pyrimido[4,5-b]indoles
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB2331988B (en) 1997-12-04 2003-04-16 Imperial College Polycyclic sulphamate inhibitors or oestrone sulphatase
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
OA12147A (en) 1998-06-02 2006-05-05 Osi Pharm Inc PyrroloÄ2,3dÜpyrimidine compositions and their use.
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
EP1731520A1 (en) * 1999-12-02 2006-12-13 OSI Pharmaceuticals, Inc. Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
SE0003795D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
GB0100622D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
AU2002360436A1 (en) 2001-11-30 2003-06-17 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors
WO2003053366A2 (en) 2001-12-20 2003-07-03 Osi Pharmaceuticals, Inc. Pyrimidine a2b selective antagonist compounds, their synthesis and use
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2005063665A1 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Propofol analogs, process for their preparation, and methods of use
ZA200606792B (en) 2004-03-04 2007-12-27 Kissei Pharmaceutical Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
NZ552093A (en) 2004-06-17 2009-06-26 Wyeth Corp Processes for preparing gonadotropin releasing hormone receptor antagonists
CA2570968A1 (en) 2004-06-17 2006-01-26 Wyeth Gonadotropin releasing hormone receptor antagonists
DE602005009209D1 (de) 2004-06-18 2008-10-02 Biolipox Ab Zur behandlung von entzündungen geeignete indole
FR2880626B1 (fr) * 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
JP2008527029A (ja) 2005-01-19 2008-07-24 バイオリポックス エービー 炎症の治療に有用なインドール類
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
FR2884824B1 (fr) 2005-04-20 2007-07-13 Sanofi Aventis Sa Derives de 1h-pyrimido[4,5-b]indole, leur preparation et leur application en therapeutique
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
KR100749216B1 (ko) * 2006-08-30 2007-08-13 위아 주식회사 4륜구동차량용 부변속기
MX2009004898A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Derivados de indol y de benzofurano-2-carboxamida.
RU2472797C2 (ru) * 2007-08-08 2013-01-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
EP2178869B1 (en) * 2007-08-17 2013-06-12 LG Life Sciences Ltd. Indole compounds as an inhibitor of cellular necrosis
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
KR101577943B1 (ko) 2008-01-31 2015-12-16 사노피 사이클릭 아자인돌-3-카복스아미드, 이들의 제조방법 및 약제로서의 이들의 용도
CL2009000241A1 (es) * 2008-02-07 2010-09-03 Chugai Pharmaceutical Co Ltd Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
EP2382207B1 (en) * 2008-11-11 2015-04-29 Xcovery Holding Company LLC Pi3k/mtor kinase inhibitors
RS55662B1 (sr) 2010-10-06 2017-06-30 Glaxosmithkline Llc Derivati benzimidazola kao inhibitori pi3 kinaze
EP2670753B1 (en) 2011-01-31 2016-10-19 Novartis AG Novel heterocyclic derivatives
KR102132574B1 (ko) 2011-03-15 2020-07-09 로렌스 리버모어 내쇼날 시큐리티, 엘엘시 트라이사이클릭 자이라제 억제제
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
PL2807165T3 (pl) 2012-01-27 2019-09-30 Université de Montréal Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych
PE20150153A1 (es) 2012-06-29 2015-02-05 Pfizer 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
SG11201607586UA (en) 2014-03-13 2016-10-28 Agency Science Tech & Res Fused pyrimidine-based hydroxamate derivatives
AU2015321654B2 (en) * 2014-09-22 2019-10-31 National Health Research Institutes Heterocyclic compounds and use thereof
CA2987974C (en) 2015-06-05 2021-10-12 Hema-Quebec Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2018039310A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
BR112020015976A2 (pt) * 2018-02-16 2020-12-15 UCB Biopharma SRL Derivados de anel 6,5 heterobicíclico farmacêutico
US20240150358A1 (en) * 2020-06-03 2024-05-09 Kineta, Inc. Purines and methods of their use
WO2021263079A1 (en) * 2020-06-26 2021-12-30 Tempest Therapeutics, Inc. Trex1 inhibitors and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864145A (en) * 1959-06-02 1961-03-29 Thomae Gmbh Dr K Novel purines and a process for their manufacture
GB1268772A (en) * 1968-03-15 1972-03-29 Glaxo Lab Ltd NOVEL alpha-CARBOLINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME
ATE140457T1 (de) * 1989-09-19 1996-08-15 Teijin Ltd Pyrrolo(2,3-d>pyrimidinderivate, verfahren zur herstellung und arzneimittelzusammensetzungen die diese enthalten

Also Published As

Publication number Publication date
EP0633886B1 (en) 2000-10-18
CZ236494A3 (en) 1994-12-15
DK0633886T3 (da) 2000-12-18
PL175347B1 (pl) 1998-12-31
ES2150941T3 (es) 2000-12-16
HUT70954A (en) 1995-11-28
DE69329574D1 (de) 2000-11-23
AU3917493A (en) 1993-11-08
FI944602A (fi) 1994-10-03
LV12794B (en) 2002-06-20
PL175327B1 (pl) 1998-12-31
EP0633886A1 (en) 1995-01-18
SK119194A3 (en) 1995-05-10
RU94042466A (ru) 1996-07-20
LV12794A (en) 2002-02-20
WO1993020078A1 (en) 1993-10-14
CA2130937A1 (en) 1993-10-14
ATE197051T1 (de) 2000-11-15
JPH08502721A (ja) 1996-03-26
GR3035188T3 (en) 2001-04-30
KR950700912A (ko) 1995-02-20
RU2103272C1 (ru) 1998-01-27
AU675932B2 (en) 1997-02-27
NO943655L (no) 1994-12-05
PT633886E (pt) 2001-03-30
MX9301847A (es) 1993-10-01
KR100284473B1 (ko) 2001-04-02
NO943655D0 (no) 1994-09-30
NO303542B1 (no) 1998-07-27
HU9402829D0 (en) 1995-02-28
DE69329574T2 (de) 2001-05-31

Similar Documents

Publication Publication Date Title
FI944602A0 (fi) Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
WO2001087329A8 (en) Liquid pharmaceutical composition containing an erythropoietin derivate
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
BR9807673A (pt) Processos para tratar asma alérgica e dermatite em um humano e composição farmacêutica.
ATE119520T1 (de) Derivate von hydroxaminsäure und von n- hydroxyharnstoff sowie ihre verwendung.
ES2053429T3 (es) El uso de buspirona para la preparacion de composiciones farmaceuticas para aliviar la ansiedad fobica.
CA2198706A1 (en) Methods for the treatment of inflammatory joint disease
EP0260305A4 (en) CHINOLINYL ETHER TETRAZOLE AS A MEDIUM FOR TREATING HYPER-SENSITIVE DISEASES.
SE9900833D0 (sv) Novel combination
EP1404281A4 (en) TOPICAL USE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND / OR MUCOSAL LESIONS, USE OF COMPOSITIONS AND COMPOUNDS IN THE TREATMENT OF SKIN AND / OR MUCOUS DISEASES
CA2368165A1 (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
CA2427814A1 (en) A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
SE9900834D0 (sv) Novel combination
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
ES2185310T3 (es) Agente antivirico herbario.
CA2404210A1 (en) Pharmaceutical gel composition
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
PT100670A (pt) Formulacoes farmaceuticas topicas de oleo-em -agua ou aquosa para o tratamento de infeccoes virais
BR9507732A (pt) Composição farmacêutica para o tratamento de glaucoma
DE69731620D1 (de) Neue substituierte n-methyl-n-(4-(4-(1h-benzimidazol-2-yl) (1,4)diazepan-1-yl)-2-(aryl)butyl)benzamide zur behandlung von allergischen krankheiten
RU95102777A (ru) Способ лечения реперфузного повреждения и "оглушения" миокарда
RU97113115A (ru) Пелоидотерапия
RU93042345A (ru) Способ лечения повреждения суставов и их последствия

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN COMPANY

FD Application lapsed